KR101609504B1 - 신경계 기능장애를 검출하기 위한 카르볼린계 및 카르바졸계 영상화제 - Google Patents

신경계 기능장애를 검출하기 위한 카르볼린계 및 카르바졸계 영상화제 Download PDF

Info

Publication number
KR101609504B1
KR101609504B1 KR1020147032388A KR20147032388A KR101609504B1 KR 101609504 B1 KR101609504 B1 KR 101609504B1 KR 1020147032388 A KR1020147032388 A KR 1020147032388A KR 20147032388 A KR20147032388 A KR 20147032388A KR 101609504 B1 KR101609504 B1 KR 101609504B1
Authority
KR
South Korea
Prior art keywords
mmol
alkyl
reaction
etoac
added
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147032388A
Other languages
English (en)
Korean (ko)
Other versions
KR20150002854A (ko
Inventor
안나 카트린 차르데닝스
하르트무트 체. 콜프
조셉 씨. 월쉬
강 첸
우메쉬 비. 간가다르마트
다날락쉬미 카시
창휘 리우
안자나 신하
에릭 왕
철 유
웨이 장
카이 첸
바니 피. 모차를라
피터 제이.에이치. 스콧
Original Assignee
일라이 릴리 앤드 캄파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US13/477,095 external-priority patent/US8932557B2/en
Application filed by 일라이 릴리 앤드 캄파니 filed Critical 일라이 릴리 앤드 캄파니
Publication of KR20150002854A publication Critical patent/KR20150002854A/ko
Application granted granted Critical
Publication of KR101609504B1 publication Critical patent/KR101609504B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/18—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted otherwise than in position 3 or 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
KR1020147032388A 2012-05-22 2012-10-25 신경계 기능장애를 검출하기 위한 카르볼린계 및 카르바졸계 영상화제 Active KR101609504B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/477,095 2012-05-22
US13/477,095 US8932557B2 (en) 2008-02-14 2012-05-22 Imaging agents for detecting neurological dysfunction
PCT/US2012/061912 WO2013176698A1 (en) 2012-05-22 2012-10-25 Carboline and carbazole based imaging agents for detecting neurological dysfunction

Publications (2)

Publication Number Publication Date
KR20150002854A KR20150002854A (ko) 2015-01-07
KR101609504B1 true KR101609504B1 (ko) 2016-04-05

Family

ID=47146722

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147032388A Active KR101609504B1 (ko) 2012-05-22 2012-10-25 신경계 기능장애를 검출하기 위한 카르볼린계 및 카르바졸계 영상화제

Country Status (9)

Country Link
EP (1) EP2852572B1 (https=)
JP (1) JP5976206B2 (https=)
KR (1) KR101609504B1 (https=)
CN (2) CN104781234A (https=)
AU (1) AU2012381042B2 (https=)
CA (1) CA2873963C (https=)
CO (1) CO7131359A2 (https=)
ES (1) ES2792830T3 (https=)
WO (1) WO2013176698A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200142215A (ko) * 2019-06-12 2020-12-22 한국과학기술연구원 타우 응집체에 선택적으로 결합하는 형광 탐침자로서 유효한 신규 화합물 및 이의 제조 방법

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015110263A1 (en) * 2014-01-21 2015-07-30 Ac Immune Sa Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyolid-like proteins
JP6762233B2 (ja) * 2014-04-22 2020-09-30 ウニヴェルシテ ド モントリオールＵｎｉｖｅｒｓｉｔｅ Ｄｅ Ｍｏｎｔｒｅａｌ 化合物および造血幹細胞および／または造血前駆細胞の増大におけるその使用
HUE053939T2 (hu) 2014-05-13 2021-08-30 Hoffmann La Roche Deuterált heterociklikus vegyületek és képalkotó kontrasztanyagként való használatuk
EA036518B1 (ru) * 2015-02-02 2020-11-18 Юсб Байофарма Спрл Производные 9h-пирролодипиридина
JP6609866B2 (ja) * 2015-03-04 2019-11-27 国立大学法人京都大学 放射性ヨウ素標識ピリド［１，２−ａ］ベンゾイミダゾール誘導体化合物
TW201707726A (zh) * 2015-08-19 2017-03-01 國立大學法人京都大學 放射性鹵素標誌吡啶并［１，２－ａ］苯并咪唑衍生物化合物
CA3003884C (en) 2015-11-13 2020-04-21 Eli Lilly And Company Azetidine derivatives for tau imaging
KR102472003B1 (ko) 2016-07-22 2022-11-29 에이씨 이뮨 에스에이 타우 단백질 응집체를 이미징하기 위한 화합물
WO2018015546A1 (en) 2016-07-22 2018-01-25 Ac Immune S.A. Compounds for imaging tau protein aggregates
WO2018024642A1 (en) 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
WO2018024643A1 (en) 2016-08-02 2018-02-08 Ucb Biopharma Sprl 9h-pyrrolo-dipyridine derivatives
MX2019005007A (es) * 2016-11-01 2019-07-18 Arvinas Inc Protac dirigidos a la proteína tau y métodos asociados de uso.
CN109884194A (zh) * 2017-12-06 2019-06-14 新疆维吾尔药业有限责任公司 一种药用植物的分离方法及其产品和应用
US20210041447A1 (en) 2018-01-24 2021-02-11 Ac Immune Sa Azacarboline compounds for the detection of tau aggregates
EP3743423A1 (en) 2018-01-24 2020-12-02 AC Immune SA Gamma-carboline compounds for the detection of tau aggregates
CN108409634B (zh) * 2018-05-10 2021-04-27 曲阜师范大学 咔唑类荧光胺类化合物标记试剂、合成和应用
JP7297053B2 (ja) 2018-08-20 2023-06-23 アルビナス・オペレーションズ・インコーポレイテッド 神経変性疾患を治療するためのｅ３ユビキチンリガーゼ結合活性を有するキメラ（ｐｒｏｔａｃ）化合物を標的とし、アルファ－シヌクレインタンパク質を標的とするタンパク質分解
EP3999182A1 (en) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
CN116003402B (zh) * 2021-11-02 2025-08-29 上海如絮生物科技有限公司 一种三环类化合物、其中间体、制备方法和应用
CN114539250B (zh) * 2022-03-04 2023-08-29 上海裕兰生物科技有限公司 一种阿尔兹海默症PET-tau示踪剂的制备方法
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
KR20250137711A (ko) 2023-02-02 2025-09-18 일라이 릴리 앤드 캄파니 타우 영상화를 위한 신규 화합물
CN117050070B (zh) * 2023-07-05 2025-10-14 湘潭大学 一种荧光探针及其制备方法和在Aβ检测中的应用
WO2025155625A1 (en) 2024-01-16 2025-07-24 Eli Lilly And Company Novel compounds for tau imaging

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125887A1 (fr) 2005-05-23 2006-11-30 Trophos Composes derives de 5h-pyrido[4,3-b]indole et leurs utilisations comme medicament pour traiter les maladies neurodegeneratives a polyglutamines
WO2011119565A1 (en) 2010-03-23 2011-09-29 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090170882A1 (en) * 2004-06-30 2009-07-02 Dashyant Dhanak Methods and compositions
DE102006062203A1 (de) * 2006-12-22 2008-06-26 Curacyte Discovery Gmbh Substituierte 5H-Pyrimido[5,4-b]indole als Induktoren der Apoptose bei B-CLL Zellen
WO2008132454A1 (en) * 2007-04-26 2008-11-06 Ge Healthcare Limited Carbolines and their use as imaging agents
EP2247558B2 (en) * 2008-02-14 2024-07-03 Eli Lilly and Company Novel imaging agents for detecting neurological dysfunction
JP2011529086A (ja) * 2008-07-24 2011-12-01 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド Ａｄ病変を同定するために有用な造影剤
JP2012051804A (ja) * 2008-12-26 2012-03-15 Kyoto Univ Ｅｇ５阻害剤
JP2012521988A (ja) * 2009-03-23 2012-09-20 シーメンス メディカル ソリューションズ ユーエスエー インコーポレイテッド 神経学的障害を検知するためのイメージング剤
US10639608B2 (en) * 2010-04-08 2020-05-05 Siemens Medical Solutions Usa, Inc. System, device and method for preparing tracers and transferring materials during radiosynthesis
JP5585382B2 (ja) * 2010-10-22 2014-09-10 コニカミノルタ株式会社 有機エレクトロルミネッセンス素子、照明装置及び表示装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006125887A1 (fr) 2005-05-23 2006-11-30 Trophos Composes derives de 5h-pyrido[4,3-b]indole et leurs utilisations comme medicament pour traiter les maladies neurodegeneratives a polyglutamines
WO2011119565A1 (en) 2010-03-23 2011-09-29 Siemens Medical Solutions Usa, Inc. Imaging agents for detecting neurological disorders

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200142215A (ko) * 2019-06-12 2020-12-22 한국과학기술연구원 타우 응집체에 선택적으로 결합하는 형광 탐침자로서 유효한 신규 화합물 및 이의 제조 방법
KR102215255B1 (ko) * 2019-06-12 2021-02-15 한국과학기술연구원 타우 응집체에 선택적으로 결합하는 형광 탐침자로서 유효한 신규 화합물 및 이의 제조 방법

Also Published As

Publication number Publication date
EP2852572B1 (en) 2020-04-01
CA2873963A1 (en) 2013-11-28
KR20150002854A (ko) 2015-01-07
CN104781234A (zh) 2015-07-15
CO7131359A2 (es) 2014-12-01
AU2012381042B2 (en) 2015-10-01
CA2873963C (en) 2017-04-11
EP2852572A1 (en) 2015-04-01
CN107011342A (zh) 2017-08-04
JP2015517572A (ja) 2015-06-22
AU2012381042A1 (en) 2014-11-20
WO2013176698A1 (en) 2013-11-28
ES2792830T3 (es) 2020-11-12
JP5976206B2 (ja) 2016-08-23

Similar Documents

Publication Publication Date Title
KR101609504B1 (ko) 신경계 기능장애를 검출하기 위한 카르볼린계 및 카르바졸계 영상화제
US8932557B2 (en) Imaging agents for detecting neurological dysfunction
ES2907992T5 (en) Novel imaging agents for detecting neurological dysfunction
KR101447795B1 (ko) 신경계 질환을 검출하기 위한 영상화제
JP3356726B2 (ja) ５ＨＴ１Ａリガンドとしてのピロロ［１，２−ａ］ピラジン誘導体
CN102046638B (zh) 检测和治疗阿尔茨海默病和相关疾病的化合物和组合物
TWI513698B (zh) 做為ｔａｕ－ｐｅｔ－配位體之二氮雜咔唑衍生物
KR20110119670A (ko) 토실레이트 전구체로부터 18ｆ―방사성표지된 스티릴피리딘의 합성 및 그로부터의 안정한 약제학적 조성물
CN103179991B (zh) 癌症的体内成像方法
CN102448933A (zh) 作为pbr配体的吲哚衍生物
WO2007033080A2 (en) Alzheimer's disease imaging agents
CN102574859A (zh) 作为体内显像剂的[18f]-标记氟马西尼类似物
MXPA04008517A (es) Compuestos terapeuticos.
CN102223900A (zh) 用于多巴胺d2受体的成像配体
HK1167393B (en) Tricyclic indole derivates as pbr ligands

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20141119

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20141119

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20151216

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20160218

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20160330

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20160330

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
FPAY Annual fee payment

Payment date: 20181227

Year of fee payment: 4

PR1001 Payment of annual fee

Payment date: 20181227

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20191227

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20210226

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20220223

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20230223

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20240226

Start annual number: 9

End annual number: 9